Meta-analysis of the impact of 9 medication classes on falls in elderly persons JC Woolcott, KJ Richardson, MO Wiens, B Patel, J Marin, KM Khan, ... Archives of internal medicine 169 (21), 1952-1960, 2009 | 1582 | 2009 |
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis CA Marra, JC Woolcott, JA Kopec, K Shojania, R Offer, JE Brazier, ... Social science & medicine 60 (7), 1571-1582, 2005 | 477 | 2005 |
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real … P Mease, C Charles-Schoeman, S Cohen, L Fallon, J Woolcott, H Yun, ... Annals of the rheumatic diseases 79 (11), 1400-1413, 2020 | 171 | 2020 |
Does physical activity reduce seniors' need for healthcare?: a study of 24 281 Canadians JC Woolcott, MC Ashe, WC Miller, P Shi, CA Marra, ... British Journal of Sports Medicine 44 (12), 902-904, 2010 | 71 | 2010 |
Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry M Agrawal, EJ Brenner, X Zhang, I Modesto, J Woolcott, RC Ungaro, ... Inflammatory bowel diseases 27 (4), 585-589, 2021 | 63 | 2021 |
Lowering generic drug prices: less regulation equals more competition AH Anis, DP Guh, J Woolcott Medical care 41 (1), 135-141, 2003 | 56 | 2003 |
The cost of fall related presentations to the ED: a prospective, in-person, patient-tracking analysis of health resource utilization JC Woolcott, KM Khan, S Mitrovic, AH Anis, CA Marra Osteoporosis international 23, 1513-1519, 2012 | 44 | 2012 |
Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada DM Skowronski, JC Woolcott, SA Tweed, RC Brunham, F Marra Vaccine 24 (19), 4222-4232, 2006 | 40 | 2006 |
The risk of venous thromboembolic events in patients with RA aged≥ 50 years with≥ 1 cardiovascular risk factor: results from a phase 3b/4 randomized safety study of … C Charles-Schoeman, R Fleischmann, E Mysler, M Greenwald, C Wang, ... Arthritis & rheumatology 73, 4064-4067, 2021 | 34* | 2021 |
Persistence of tofacitinib in the treatment of rheumatoid arthritis in open‐label, long‐term extension studies up to 9.5 years JE Pope, E Keystone, S Jamal, L Wang, L Fallon, J Woolcott, I Lazariciu, ... ACR Open Rheumatology 1 (2), 73-82, 2019 | 33* | 2019 |
Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View MC Dubinsky, K Watanabe, P Molander, L Peyrin-Biroulet, M Rubin, ... Inflammatory bowel diseases 27 (11), 1747-1755, 2021 | 29 | 2021 |
Cost‐utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: Economic evaluation of a cluster randomized controlled trial study CA Marra, M Grubisic, J Cibere, KA Grindrod, JC Woolcott, L Gastonguay, ... Arthritis Care & Research 66 (6), 810-816, 2014 | 28 | 2014 |
Ulcerative colitis narrative global survey findings: communication gaps and agreements between patients and physicians DT Rubin, A Hart, R Panaccione, A Armuzzi, U Suvanto, JJ Deuring, ... Inflammatory bowel diseases 27 (7), 1096-1106, 2021 | 24 | 2021 |
Longterm drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis P Emery, B Vlahos, P Szczypa, M Thakur, HE Jones, J Woolcott, ... The Journal of Rheumatology 47 (4), 493-501, 2020 | 24 | 2020 |
Safety and cost benefit of same-day discharge after percutaneous coronary intervention S Khatri, JG Webb, RG Carere, A Amis, J Woolcott, S Chugh, ... American Journal of Cardiology 90 (4), 425-427, 2002 | 24 | 2002 |
Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making PC Taylor, N Betteridge, TM Brown, J Woolcott, AJ Kivitz, C Zerbini, ... Patient preference and adherence, 119-131, 2020 | 22 | 2020 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy AH Anis, H Sun, S Singh, J Woolcott, B Nosyk, M Brisson Pharmacoeconomics 24, 387-400, 2006 | 22 | 2006 |
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years J Pope, L Bessette, N Jones, L Fallon, J Woolcott, D Gruben, M Crooks, ... Rheumatology 59 (3), 568-574, 2020 | 21 | 2020 |
Predictors of sustained response with tofacitinib therapy in patients with ulcerative colitis WJ Sandborn, A Armuzzi, G Liguori, PM Irving, AI Sharara, R Mundayat, ... Inflammatory Bowel Diseases 28 (9), 1338-1347, 2022 | 18 | 2022 |
Real-world experience with tofacitinib versus adalimumab and etanercept in biologic-naive patients with RA previously treated with methotrexate: data from a US administrative … T Smith, J Harnett, D Gruben, C Chen, E Agarwal, J Woolcott ARTHRITIS & RHEUMATOLOGY 69, 2017 | 15 | 2017 |